Connection
Charles Daley to Tuberculosis, Pulmonary
This is a "connection" page, showing publications Charles Daley has written about Tuberculosis, Pulmonary.
|
|
Connection Strength |
|
|
|
|
|
4.466 |
|
|
|
-
Griffith DE, Daley CL. Treatment of Mycobacterium abscessus Pulmonary Disease. Chest. 2022 01; 161(1):64-75.
Score: 0.742
-
Daley CL, Glassroth J. Treatment of pulmonary nontuberculous mycobacterial infections: many questions remain. Ann Am Thorac Soc. 2014 Jan; 11(1):96-7.
Score: 0.439
-
Chang KC, Leung CC, Daley CL. Linezolid for multidrug-resistant tuberculosis - authors' reply. Lancet Infect Dis. 2013 Jan; 13(1):16-7.
Score: 0.410
-
Chang KC, Leung CC, Daley CL. Linezolid for multidrug-resistant tuberculosis. Lancet Infect Dis. 2012 Jul; 12(7):502-3.
Score: 0.396
-
Nahid P, Jarlsberg LG, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL. Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infect Dis. 2011 Jan 03; 11:1.
Score: 0.357
-
Nahid P, Daley CL. Prevention of tuberculosis in HIV-infected patients. Curr Opin Infect Dis. 2006 Apr; 19(2):189-93.
Score: 0.257
-
Marras TK, Daley CL. A systematic review of the clinical significance of pulmonary Mycobacterium kansasii isolates in HIV infection. J Acquir Immune Defic Syndr. 2004 Aug 01; 36(4):883-9.
Score: 0.229
-
Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med. 2004 Sep 01; 170(5):561-6.
Score: 0.226
-
Ong A, Creasman J, Hopewell PC, Gonzalez LC, Wong M, Jasmer RM, Daley CL. A molecular epidemiological assessment of extrapulmonary tuberculosis in San Francisco. Clin Infect Dis. 2004 Jan 01; 38(1):25-31.
Score: 0.218
-
Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 11 15; 200(10):e93-e142.
Score: 0.165
-
Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, Horsburgh R, Lange C, Lienhardt C, Oren E, Podewils LJ, Seaworth B, van den Hof S, Daley CL, Gebhard AC, Wares F. Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS One. 2016; 11(5):e0155968.
Score: 0.130
-
Haas MK, Daley CL. Mycobacterial Lung Disease Complicating HIV Infection. Semin Respir Crit Care Med. 2016 Apr; 37(2):230-42.
Score: 0.128
-
Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, Ayakaka I, Van TT, Voskuil MI, de Jong BC, Davidson RM, Fingerlin TE, Kechris K, Palmer C, Nahid P, Daley CL, Geraci M, Huang L, Cattamanchi A, Strong M, Schoolnik GK, Davis JL. Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis. J Infect Dis. 2015 Sep 15; 212(6):990-8.
Score: 0.119
-
Daley CL. Global scale-up of the programmatic management of multidrug-resistant tuberculosis. Indian J Tuberc. 2014 Apr; 61(2):108-15.
Score: 0.112
-
Martiniano SL, Sontag MK, Daley CL, Nick JA, Sagel SD. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc. 2014 Jan; 11(1):36-44.
Score: 0.110
-
Wu B, Huang C, Kato-Maeda M, Hopewell PC, Daley CL, Krensky AM, Clayberger C. IL-24 modulates IFN-gamma expression in patients with tuberculosis. Immunol Lett. 2008 Apr 15; 117(1):57-62.
Score: 0.072
-
Winthrop KL, Daley CL, Griffith D. Nontuberuclous mycobacterial disease: updated diagnostic criteria for an under-recognized infectious complication of anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol. 2007 Oct; 3(10):E1.
Score: 0.071
-
Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006 Aug 01; 174(3):331-8.
Score: 0.065
-
Ong A, Rudoy I, Gonzalez LC, Creasman J, Kawamura LM, Daley CL. Tuberculosis in healthcare workers: a molecular epidemiologic study in San Francisco. Infect Control Hosp Epidemiol. 2006 May; 27(5):453-8.
Score: 0.064
-
Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006 Jun 01; 173(11):1283-9.
Score: 0.064
-
Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan 15; 64(2):111-115.
Score: 0.034
-
Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan 15; 64(2):e1-e33.
Score: 0.034
-
Collard HR, Morris A, Daley CL, Humbert M, Meyer KC. Clinical year in review IV: HIV, mycobacterial disease, pulmonary hypertension, and interstitial lung disease. Proc Am Thorac Soc. 2012 Oct; 9(4):204-9.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|